Serine and Fenofibrate Study in Patients With MacTel Type 2
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2a study of the effect of serine supplementation and fenofibrate treatment on
serum deoxysphingolipid levels in patients with macular telangiectasia type 2 (MacTel). This
study involves six arms. Participants will be randomly assigned to one of the following
treatment groups: serine 200 mg/kg/day, serine 400 mg/kg/day, fenofibrate 160 mg/day, both
serine 200 mg/kg/day and fenofibrate 160 mg/day, both serine 400 mg/kg/day and fenofibrate
160 mg/day, or no treatment (control group). Serum deoxysphingolipid levels will be used as
the primary outcome, and safety will be evaluated. The participants will be followed for 10
weeks, with visits at Screening, Week 0, 3, 6 and 10.